Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly anticounterfeit measures

Executive Summary

Lilly is exploring use of radio frequency identification on its products in pilot programs as part of multi-pronged anticounterfeit strategy. Other measures include Canadian supply allocation program, direct-buying requirement for wholesalers, and establishment of a global product protection division. The company's Feb. 5 press release describing the measures will be submitted to House Energy & Commerce Committee as requested under its counterfeit drug investigation (1"The Pink Sheet" Jan. 19, 2004, p. 13). Lilly's Zyprexa, Cialis and insulin products have been the subject of counterfeit concerns...

You may also be interested in...

Manufacturers’ Anticounterfeiting Plans Sought In House Cmte. Investigation

The House Energy & Commerce Committee is asking five brand-name drug manufacturers to submit information on their efforts to prevent counterfeiting

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.

QUOTED. 28 February 2020. Jubilee Brown.

Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts